^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Pembroria (pembrolizumab biosimilar)

    i
    Other names: BCD-201, BCD 201, BCD201
    Associations

    News

    Trials
    Company:
    Biocad
    Drug class:
    PD1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    1year
    Clinical Study of the Efficacy and Safety of BCD-201 and Keytruda in Subjects With Advanced Melanoma (clinicaltrials.gov)
    P3, N=366, Active, not recruiting, Biocad | Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2023 --> Dec 2023
    Enrollment closed • Trial primary completion date • Metastases
    |
    PROCR (Protein C Receptor)
    |
    Keytruda (pembrolizumab) • Pembroria (pembrolizumab biosimilar)
    over1year
    NRG-GI002: Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer (clinicaltrials.gov)
    P2, N=363, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2023 --> Mar 2024
    Trial completion date • Metastases
    |
    Keytruda (pembrolizumab) • capecitabine • oxaliplatin • veliparib (ABT-888) • leucovorin calcium • fluorouracil topical • Pembroria (pembrolizumab biosimilar)
    over1year
    NCI-2020-01016: BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia (clinicaltrials.gov)
    P2, N=76, Active, not recruiting, National Cancer Institute (NCI) | Suspended --> Active, not recruiting
    Enrollment closed • Combination therapy • Tumor mutational burden
    |
    Chr t(15;17)
    |
    Keytruda (pembrolizumab) • Venclexta (venetoclax) • azacitidine • Pembroria (pembrolizumab biosimilar)
    over1year
    Double-Blind, Randomized Clinical Trial to Evaluate the PK and Safety of BCD-201 and Keytruda® in Patients With Advanced Malignancies (clinicaltrials.gov)
    P1, N=131, Active, not recruiting, Biocad
    New P1 trial • Metastases
    |
    PD-L1 (Programmed death ligand 1) • PROCR (Protein C Receptor)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Pembroria (pembrolizumab biosimilar)